Rational development of a stable liquid formulation for nanomedicine products.
about
Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virusSingle DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individualsDermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes.DNA nanoparticles with core-shell morphology.Structure and biological activity of pathogen-like synthetic nanomedicines.Immunotherapy with an HIV-DNA Vaccine in Children and Adults.Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.Cationic polymers and their therapeutic potential.No king without a crown--impact of the nanomaterial-protein corona on nanobiomedicine.Understanding and exploiting nanoparticles' intimacy with the blood vessel and blood.Use of the polycation polyethyleneimine to improve the physical properties of alginate-hyaluronic acid hydrogel during fabrication of tissue repair scaffolds.Optimized preparation of pDNA/poly(ethylene imine) polyplexes using a microfluidic system.Linear Polyethyleneimine: Optimized Synthesis and Characterization - On the Way to “Pharmagrade” Batches
P2860
Q27329490-3FAFFA4E-05B3-4AD1-91A2-6C4A8B1C8380Q28730050-D66211F7-F4D2-4AC5-B727-055C873F24F1Q30408029-21BC2D9C-127C-4713-9840-314B213BD44DQ35087579-03E5FB98-308C-4D83-A99F-D85CCD2EF866Q35138155-1A80FC57-D79D-4961-9B6C-685DA36312E1Q35144051-58937902-1141-4B0D-AF82-036CF9A87694Q35742894-970D6627-3940-4EBF-A749-07AC81AF70DAQ35826642-1DC1E9D4-4702-402F-A120-FC6C445AA392Q37381097-993570CA-60E7-4672-A605-A55C75CEB7A0Q38033969-FCCC4A0F-FED1-4342-B941-A46F9E321F95Q38364473-22DBCF6B-287B-4697-B9E7-07723DBA6F44Q38560337-B1F700E5-2BA5-4069-BE82-564225C5121BQ38911833-6DD4BC9D-1A17-4BA4-8160-254713C8197AQ45878937-E2D6D1CA-5A42-4982-BC6A-3374E8AD240DQ58385676-5F0BAE8D-904F-4404-ADCF-CD1E582D8204
P2860
Rational development of a stable liquid formulation for nanomedicine products.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Rational development of a stable liquid formulation for nanomedicine products.
@en
Rational development of a stable liquid formulation for nanomedicine products.
@nl
type
label
Rational development of a stable liquid formulation for nanomedicine products.
@en
Rational development of a stable liquid formulation for nanomedicine products.
@nl
prefLabel
Rational development of a stable liquid formulation for nanomedicine products.
@en
Rational development of a stable liquid formulation for nanomedicine products.
@nl
P2093
P1476
Rational development of a stable liquid formulation for nanomedicine products.
@en
P2093
Eniko R Toke
Eszter Somogyi
Julianna Lisziewicz
Orsolya Lorincz
P304
P356
10.1016/J.IJPHARM.2010.03.048
P407
P577
2010-03-25T00:00:00Z